We propose that the improved renal phosphate reabsorption and vitamin D synthesis associated with burosumab-mediated inhibition of FGF23 results in better healing of rickets and osteomalacia, which are fundamental for correcting lower limb malalignment. The gene discussed is FGF23; the disease is osteomalacia.